BetterLife Pharma (CSE: BETR; OTCQB: BETRF; FSE: NPAU) has appointed its current corporate advisor, Doug Drysdale, as executive chairman and director.
Mr. Drysdale was formerly CEO of Cybin (NYSE: CYBN) where he led the company’s strategy and team expansion, taking it from molecule inception to Phase 3 trials in just three years. He is known as a vocal advocate for revolutionizing mental healthcare through numerous speaking engagements, panel participations, and media interviews.
In a statement, Ahmad Doroudian, CEO of BetterLife, commented, “We are delighted to welcome Doug to our Board of Directors. His proven global leadership, underscored by a track record of executing multiple successful transactions across diverse markets and therapeutic indications, brings a depth of strategic insight and operational expertise that will meaningfully strengthen BetterLife. Doug’s experience navigating complex deal environments and scaling opportunities across jurisdictions will be invaluable as we continue to advance our growth strategy and create long-term shareholder value.”
